KRRO Quote, Financials, Valuation and Earnings

CalAmp has a net margin of -- compared to Korro Bio's net margin of --. Korro Bio's return on equity of -- beat CalAmp's return on equity of --.

Korro Bio has a consensus price target of $137.76, signalling upside risk potential of 218.22%. On the other hand CalAmp has an analysts' consensus of -- which suggests that it could fall by --. Given that Korro Bio has higher upside potential than CalAmp, analysts believe Korro Bio is more attractive than CalAmp.

Korro Bio has a beta of 1.975, which suggesting that the stock is 97.516% more volatile than S&P 500. In comparison CalAmp has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CalAmp offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. CalAmp pays out -- of its earnings as a dividend.

Korro Bio quarterly revenues are --, which are smaller than CalAmp quarterly revenues of --. Korro Bio's net income of -$21M is higher than CalAmp's net income of --. Notably, Korro Bio's price-to-earnings ratio is -- while CalAmp's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus -- for CalAmp. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -- compared to Korro Bio's net margin of --. Korro Bio's return on equity of -- beat CEL-SCI's return on equity of --.

Korro Bio has a consensus price target of $137.76, signalling upside risk potential of 218.22%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 1007.93%. Given that CEL-SCI has higher upside potential than Korro Bio, analysts believe CEL-SCI is more attractive than Korro Bio.

Korro Bio has a beta of 1.975, which suggesting that the stock is 97.516% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Korro Bio quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Korro Bio's net income of -$21M is lower than CEL-SCI's net income of -$6.9M. Notably, Korro Bio's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Korro Bio's net margin of -416.75%. Korro Bio's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Korro Bio has a consensus price target of $137.76, signalling upside risk potential of 218.22%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 903.48%. Given that IGC Pharma has higher upside potential than Korro Bio, analysts believe IGC Pharma is more attractive than Korro Bio.

Korro Bio has a beta of 1.975, which suggesting that the stock is 97.516% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Korro Bio quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Korro Bio's net income of -$21M is lower than IGC Pharma's net income of -$1.7M. Notably, Korro Bio's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus 21.86x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Korro Bio's net margin of -49.65%. Korro Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Korro Bio has a consensus price target of $137.76, signalling upside risk potential of 218.22%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Korro Bio, analysts believe NovaBay Pharmaceuticals is more attractive than Korro Bio.

Korro Bio has a beta of 1.975, which suggesting that the stock is 97.516% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Korro Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Korro Bio's net income of -$21M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Korro Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.